slave1, first of all a big Thank You for your insights. So to dumb it down for investors like me, NWBO submitted dc-vax initially for glioblastoma treatment, using the old manufacturing system. Since then, the MHRA has considered the success of dc-vax for other types of cancer being treated under compassionate care and started working with NWBO to expand the scope beyond just for glioblastoma. They will use Sl87 to justify this. The submission was under the old manufacturing process, but they upped the scope to include flaskworks and advent as the same source allowing for flaskworks to be phased in. Nice is not acting until they receive smpc, which is being written in coordination with NWBO as we speak. NWBO will remain silent until smpc is locked. So the extra time its taken for approval is due to the scope of dc-vax for multiple cancers. Am I getting it so far?
Market Data 
Markets 
AI
